Cetuximab increases LGR5 expression and augments LGR5-targeting antibody-drug conjugate efficacy in patient-derived colorectal cancer models

Summary: Colorectal cancer (CRC) remains the second-leading cause of cancer-associated deaths, indicating an urgent need for improved therapeutic options. We previously generated antibody-drug conjugates (ADCs) targeting the cancer stem-like cell marker leucine-rich repeat-containing G protein-coupl...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Peyton C. High, Zhengdong Liang, Cara Guernsey-Biddle, Shraddha Subramanian, Yueh-Ming Shyu, Adela M. Aldana, Yukimatsu Toh, Kendra S. Carmon
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2025-10-01
Edice:	Cell Reports Medicine
Témata:	antibody-drug conjugate LGR5 EGFR colorectal cancer combination treatment cetuximab
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2666379125004367
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!